SCHEMBL2599124

SCHEMBL2599124

C/C=C(\O[Si](C)(C)C(C)(C)C)c1cccc(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
PARP1 P09874 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
MTNR1A P48039 2/20 0.41
MTNR1B P49286 2/20 0.41
MAOB P27338 1/20 0.40
TP53 P04637 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599129 1.00 PRSS1 (0.47) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL15007498 0.82 PARP1 (0.39) PARP1MEN1KMT2A
SCHEMBL15007497 0.82 PARP1 (0.39) PARP1MEN1KMT2A
SCHEMBL1683161 0.81 SLC6A2 (0.38) PARP1MAOBALDH1A1L3MBTL1
SCHEMBL1683164 0.81 SLC6A2 (0.38) PARP1MAOBALDH1A1L3MBTL1
SCHEMBL2599448 0.81 PTGS1 (0.40) CES2CES1NPC1RAB9APARP1
SCHEMBL15007508 0.81 C1S (0.41) NPC1RAB9APARP1TP53ALDH1A1
SCHEMBL15007507 0.81 C1S (0.41) NPC1RAB9APARP1TP53ALDH1A1
SCHEMBL2599449 0.81 PTGS1 (0.40) CES2CES1NPC1RAB9APARP1
SCHEMBL15007496 0.79 ALDH1A1 (0.34) CES1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9527823-B2 Hydroxybupropion analogues for treating drug dependence RESEARCH TRIANGLE INSTITUTE (US) 2016-12-27 US disclosed
EP-2571859-B1 1-PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE RES TRIANGLE INST (US) 2015-07-22 EP disclosed
US-20150141416-A1 HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE RESEARCH TRIANGLE INSTITUTE 2015-05-21 US disclosed
US-8906908-B2 Hydroxybupropion analogues for treating drug dependence RESEARCH TRIANGLE INSTITUTE (US) 2014-12-09 US disclosed
US-20130150357-A1 HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE RESEARCH TRIANGLE INSTITUTE (US) 2013-06-13 US disclosed
EP-2571859-A2 HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE Research Triangle Institute (US) 2013-03-27 EP disclosed
WO-2011146821-A2 1 - PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE RESEARCH TRIANGLE INSTITUTE (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150357-A1 HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE SLC6A2, SLC6A3, HTR3B PRSS1 3748/4885PRSS2 4691/4885PRSS3 3633/4885
US-20150141416-A1 HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE SLC6A2, SLC6A3, HTR3B PRSS1 3748/4885PRSS2 4691/4885PRSS3 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.